Search Results - "Flandre, P" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

by Nguyen, T, Fofana, D B, Lê, M P, Charpentier, C, Peytavin, G, Wirden, M, Lambert-Niclot, S, Desire, N, Grude, M, Morand-Joubert, L, Flandre, P, Katlama, C, Descamps, D, Calvez, V, Todesco, E, Marcelin, A G
Published in Journal of antimicrobial chemotherapy (01.09.2018)

Get full text

Journal Article

HIV MDR is still a relevant issue despite its dramatic drop over the years

HIV MDR is still a relevant issue despite its dramatic drop over the years

by Armenia, D, Di Carlo, D, Flandre, P, Bouba, Y, Borghi, V, Forbici, F, Bertoli, A, Gori, C, Fabeni, L, Gennari, W, Pinnetti, C, Mondi, A, Cicalini, S, Gagliardini, R, Vergori, A, Bellagamba, R, Malagnino, V, Montella, F, Colafigli, M, Latini, A, Marocco, R, Licthner, M, Andreoni, M, Mussini, C, Ceccherini-Silberstein, F, Antinori, A, Perno, C F, Santoro, M M
Published in Journal of antimicrobial chemotherapy (01.05.2020)

Get full text

Journal Article

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination

by Lambert-Niclot, S, Allavena, C, Grude, M, Flandre, P, Sayon, S, Andre, E, Wirden, M, Rodallec, A, Jovelin, T, Katlama, C, Calvez, V, Raffi, F, Marcelin, A-G
Published in Journal of antimicrobial chemotherapy (01.08.2016)

Get full text

Journal Article

Comparison of 48‐week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor‐sparing regimens: a systematic review and network meta‐analysis

Comparison of 48‐week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor‐sparing regimens: a systematic review and network meta‐analysis

by Gallien, S, Massetti, M, Flandre, P, Leleu, H, Descamps, D, Lazaro, E
Published in HIV medicine (01.09.2018)

Get full text

Journal Article

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

by Lambert-Niclot, S, Charpentier, C, Storto, A, Fofana, D B, Soulié, C, Fourati, S, Visseaux, B, Wirden, M, Morand-Joubert, L, Masquelier, B, Flandre, P, Calvez, V, Descamps, D, Marcelin, A-G
Published in Journal of antimicrobial chemotherapy (01.06.2013)

Get full text

Journal Article

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

by Valantin, M. A., Lambert-Niclot, S., Flandre, P., Morand-Joubert, L., Cabiè, A., Meynard, J. L., Ponscarme, D., Ajana, F., Slama, L., Curjol, A., Cuzin, L., Schneider, L., Taburet, A. M., Marcelin, A. G., Katlama, C.
Published in Journal of antimicrobial chemotherapy (01.03.2012)

Get full text

Journal Article

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving Integrase Inhibitors

by Gaillet, A., Calin, R., Flandre, P., Tubiana, R., Valantin, M.-A., Caumes, E., Katlama, C., Pourcher, V.
Published in Infectious diseases now (Online) (01.02.2021)

Get full text

Journal Article

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

by Lambert-Niclot, S., Charpentier, C., Storto, A., Fofana, D., Soulie, C., Fourati, S., Wirden, M., Morand-Joubert, L., Masquelier, B., Flandre, P., Calvez, V., Descamps, D., Marcelin, A. G.
Published in Journal of antimicrobial chemotherapy (01.04.2014)

Get full text

Journal Article

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

by Briot, K, Kolta, S, Flandre, P, Boué, F, Ngo Van, P, Cohen-Codar, I, Norton, M, Delfraissy, J.F, Roux, C
Published in Bone (New York, N.Y.) (01.05.2011)

Get full text

Journal Article

Virological failure of patients on maraviroc-based antiretroviral therapy

Virological failure of patients on maraviroc-based antiretroviral therapy

by Raymond, Stéphanie, Maillard, Anne, Amiel, Corinne, Peytavin, Gilles, Trabaud, Mary Anne, Desbois, Delphine, Bellecave, Pantxika, Delaugerre, Constance, Soulie, Cathia, Marcelin, Anne Geneviève, Descamps, Diane, Izopet, Jacques
Published in Journal of antimicrobial chemotherapy (01.06.2015)

Get full text

Journal Article

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial

Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial

by Ghosn, J, Flandre, P, Cohen‐Codar, I, Girard, P‐M, Chaix, M‐L, Raffi, F, Dellamonica, P, NgoVan, P, Norton, M, Delfraissy, J‐F
Published in HIV medicine (01.02.2010)

Get full text

Journal Article

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

by Vingerhoets, J, Calvez, V, Flandre, P, Marcelin, A‐G, Ceccherini‐Silberstein, F, Perno, C‐F, Mercedes Santoro, M, Bateson, R, Nelson, M, Cozzi‐Lepri, A, Grarup, J, Lundgren, J, Incardona, F, Kaiser, R, Sonnerborg, A, Clotet, B, Paredes, R, Günthard, HF, Ledergerber, B, Hoogstoel, A, Nijs, S, Tambuyzer, L, Lavreys, L, Opsomer, M
Published in HIV medicine (01.05.2015)

Get full text

Journal Article

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy

by Valantin, MA, Kolta, S, Flandre, P, Algarte Genin, M, Meynard, JL, Ponscarme, D, Slama, L, Cuzin, L, Kerviler, E, Inaoui, R, Katlama, C
Published in HIV medicine (01.09.2012)

Get full text

Journal Article

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy

by FLANDRE, P
Published in AIDS (London) (25.02.1999)

Get full text

Journal Article

Salivary Cytomegalovirus (CMV) Shedding, Glycoprotein B Genotype Distribution, and CMV Disease in Human Immunodeficiency Virus-Seropositive Patients

Salivary Cytomegalovirus (CMV) Shedding, Glycoprotein B Genotype Distribution, and CMV Disease in Human Immunodeficiency Virus-Seropositive Patients

by Fidouh-Houhou, N., Duval, X., Bissuel, F., Bourbonneux, V., Flandre, P., Ecobichon, J. L., Jordan, M. C., Vildé, J. L., Brun-Vézinet, F., Leport, C.
Published in Clinical infectious diseases (15.10.2001)

Get full text

Journal Article

National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation

National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation

by Delaugerre, C., Flandre, P., Marcelin, A.G., Descamps, D., Tamalet, C., Cottalorda, J., Schneider, V., Yerly, S., LeGoff, J., Morand-Joubert, L., Chaix, M.L., Costagliola, D., Calvez, V.
Published in Journal of medical virology (01.05.2008)

Get full text

Journal Article

Analysing survival in the presence of an auxiliary variable

Analysing survival in the presence of an auxiliary variable

by Flandre, P
Published in Statistics in medicine (30.01.1998)

Get full text

Journal Article

Estimating the proportion of treatment effect explained by a surrogate marker

Estimating the proportion of treatment effect explained by a surrogate marker

by Flandre, P, Saidi, Y
Published in Statistics in medicine (15.01.1999)

Get full text

Journal Article

Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL

Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL

by Gasquet, I, Flandre, P, Heurtebize, N, Deal, C, Perrin, E, Chartier, F, Fourrier-Réglat, A
Published in Encéphale (01.02.2009)

Get more information

Journal Article

Cytomegalovirus (CMV) Viremia and the CD4+ Lymphocyte Count as Predictors of CMV Disease in Patients Infected with Human Immunodeficiency Virus

Cytomegalovirus (CMV) Viremia and the CD4+ Lymphocyte Count as Predictors of CMV Disease in Patients Infected with Human Immunodeficiency Virus

by Gérard, L., Leport, C., Flandre, P., Houhou, N., Salmon-Céron, D., Pépin, J. M., Mandet, C., Brun-Vézinet, F., Vildé, J. L.
Published in Clinical infectious diseases (01.05.1997)

Get full text

Journal Article

1
2
3
4
5
6
7
Next
[7]